Skip to main content

Table 1 Human samples

From: The apolipoprotein receptor LRP3 compromises APP levels

 

Age (y)

Gender

PM (h)

SP

ApoE

MA NFT

 0

46

f

9.5

0

ɛ2/ɛ3

46

m

15

ɛ3/ɛ4

47

m

5

ɛ3/ɛ3

49

m

7.5

ɛ3/ɛ3

50

m

17

ɛ3/ɛ3

52

m

5

ɛ3/ɛ3

52

f

6

ɛ4/ɛ4

53

m

7.5

ɛ3/ɛ3

56

m

4

ɛ2/ɛ3

59

m

6,5

ɛ3/ɛ3

60

f

11.5

ɛ3/ɛ3

AD NFT

 Braak I

53

m

6.25

A

ɛ3/ɛ4

64

m

8.5

0

ɛ3/ɛ3

67

m

14.5

0

ɛ3/ɛ3

68

m

11

0

ɛ2/ɛ3

 Braak II

57

m

4.5

0

ɛ3/ɛ4

60

f

9.5

A

ɛ3/ɛ3

65

m

16.5

0

ɛ3/ɛ3

67

m

7.25

0

ɛ3/ɛ4

69

m

3.5

A

ɛ3/ɛ4

72

m

6.25

A

ɛ3/ɛ4

74

m

5.5

A

ɛ2/ɛ3

78

m

16

0

ɛ3/ɛ3

78

m

10.75

B

ɛ3/ɛ4

86

m

5.5

A

ɛ2/ɛ3

 Braak III

68

f

4.5

A

ɛ3/ɛ3

71

m

7.5

0

ɛ2/ɛ3

73

m

4

0

ɛ3/ɛ3

76

f

4

B

ɛ3/ɛ3

77

m

13.5

C

ɛ3/ɛ4

77

m

5.5

A

ɛ3/ɛ3

79

f

3.5

B

ɛ3/ɛ3

82

f

5

A

ɛ3/ɛ3

90

f

4

B

ɛ3/ɛ3

 Braak IV

79

m

5

A

ɛ4/ɛ4

81

f

5

C

ɛ3/ɛ3

85

m

14

B

ɛ3/ɛ4

89

m

3.5

B

ɛ3/ɛ4

99

f

5

B

ɛ3/ɛ3

 Braak V

72

m

2.75

C

ɛ3/ɛ4

73

m

4.5

B

ɛ3/ɛ4

74

f

9

A

ɛ3/ɛ4

75

m

11.5

B

ɛ3/ɛ4

77

m

16

C

ɛ3/ɛ3

78

m

17

0

ɛ3/ɛ3

81

f

5.5

C

ɛ3/ɛ4

87

m

7

C

ɛ3/ɛ3

93

m

3

C

ɛ3/ɛ3

 Braak VI

56

f

7

C

ɛ3/ɛ3

67

f

8

C

ɛ3/ɛ4

86

f

20.5

C

ɛ3/ɛ3

  1. Middle-aged (MA) cases and cases with AD-related pathology (AD). Subjects were categorized according to the Braak stage of neurofibrillary tangle (NFT I–VI) and senile plaque staging (0–C) [18, 19]. Age (y years), gender (m male, f female), post-mortem (PM, h hours), SP senile plaques, APOE (APOE alleles, ɛ2, ɛ3, and ɛ4)